Several PI3K inhibitors (idelalisib, copanlisib) were approved for the therapy of various lymphoproliferative malignancies, while AKT inhibitors (capivasertib, ipatasertib) were recently approved for clinical use in breast cancer patients [33]. Here, AKT1 is linked to breast carcinoma.